Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-53718678 in HSCT Recipients with RSV Upper Respiratory Tract Infection
jRCT2080225122Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2020
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of rilematovir in respiratory syncytial virus disease (RSV) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Clinical outcomes, Antiviral activity and 3 more. Started Mar 2020; status: completed.
02
Drugs
rilematovir
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on jRCT2080225122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225122.